Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Thomas R EinarsonBasil G BerezaFadi TedouriKristel Van ImpeTom R DeneePieter J T DriesPublished in: Journal of medical economics (2017)
PP3M dominated all commonly used drugs. It is cost-effective for treating chronic schizophrenia in the Netherlands. Results were robust over a wide range of sensitivity analyses. For patients requiring a depot medication, such as those with adherence problems, PP3M appears to be a good alternative anti-psychotic treatment.